IRIDEX CORP (IRIX)
US4626841013 - Common Stock
We assign a fundamental rating of 2 out of 10 to IRIX. IRIX was compared to 193 industry peers in the Health Care Equipment & Supplies industry. While IRIX seems to be doing ok healthwise, there are quite some concerns on its profitability. IRIX does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
IRIX had negative earnings in the past year.
IRIX had a negative operating cash flow in the past year.
In the past 5 years IRIX always reported negative net income.
IRIX had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
IRIX's Return On Assets of -27.80% is in line compared to the rest of the industry. IRIX outperforms 46.88% of its industry peers.
Looking at the Return On Equity, with a value of -100.55%, IRIX is doing worse than 69.27% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -27.8% | ||
| ROE | -100.55% | ||
| ROIC | N/A |
ROA(3y)-18.8%
ROA(5y)-20.86%
ROE(3y)-55.59%
ROE(5y)-48.4%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of IRIX (42.03%) is worse than 61.98% of its industry peers.
IRIX's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for IRIX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 42.03% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.6%
GM growth 5Y0.5%
2. Health
2.1 Basic Checks
IRIX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, IRIX has more shares outstanding
IRIX has more shares outstanding than it did 5 years ago.
There is no outstanding debt for IRIX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -1.06, we must say that IRIX is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of IRIX (-1.06) is worse than 60.94% of its industry peers.
IRIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.06 |
ROIC/WACCN/A
WACC9.72%
2.3 Liquidity
A Current Ratio of 2.12 indicates that IRIX has no problem at all paying its short term obligations.
IRIX's Current ratio of 2.12 is on the low side compared to the rest of the industry. IRIX is outperformed by 72.40% of its industry peers.
IRIX has a Quick Ratio of 1.35. This is a normal value and indicates that IRIX is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.35, IRIX is doing worse than 72.92% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.12 | ||
| Quick Ratio | 1.35 |
3. Growth
3.1 Past
The earnings per share for IRIX have decreased strongly by -25.53% in the last year.
IRIX shows a decrease in Revenue. In the last year, the revenue decreased by -8.97%.
IRIX shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.02% yearly.
EPS 1Y (TTM)-25.53%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-157.14%
Revenue 1Y (TTM)-8.97%
Revenue growth 3Y12.58%
Revenue growth 5Y4.02%
Revenue growth Q2Q-18.04%
3.2 Future
Based on estimates for the next years, IRIX will show a very strong growth in Earnings Per Share. The EPS will grow by 22.42% on average per year.
IRIX is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -0.37% yearly.
EPS Next Y36.03%
EPS Next 2Y22.42%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-4.6%
Revenue Next 2Y-0.37%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for IRIX. In the last year negative earnings were reported.
Also next year IRIX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
IRIX's earnings are expected to grow with 22.42% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.42%
EPS Next 3YN/A
5. Dividend
5.1 Amount
IRIX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
IRIDEX CORP
NASDAQ:IRIX (5/6/2024, 7:08:02 PM)
2.805
+0.01 (+0.18%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap45.58M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -27.8% | ||
| ROE | -100.55% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 42.03% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover1.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.12 | ||
| Quick Ratio | 1.35 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-25.53%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y36.03%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-8.97%
Revenue growth 3Y12.58%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y